Revlimid
information and resources from the National Cancer Institute
Revlimid
(Other name for: lenalidomide)
|
|
|
|
news articles
Stocks soar to unfamiliar heights 01 Apr 2006
NorthJersey.com, Celgene's blood cancer drug Revlimid, which is expected to be a big seller, was approved by federal regulators in late 2005. Iselin-based Engelhard Corp. ...
Celgene's Revlimid Has Upside Long-Term Potential Mar 8, 2006
Forbes Morgan Stanley raised the price target on Celgene to $48 from $35.50, citing overlooked potential for the company's cancer drug Revlimid. ...
Celgene gets Revlimid priority review Mar 3, 2006
BusinessWeek ...said Friday that the Food and Drug Administration will give a priority review to its drug Revlimid to treat cancer of the plasma cells found in bone marrow. ...
FDA Grants Priority Review for REVLIMID(R) sNDA for Treatment of ... Mar 3, 2006
International News Service, US Food and Drug Administration (FDA) has granted a Priority Review designation to its Supplemental New Drug Application (sNDA) for REVLIMID (lenalidomide) for ...
Celgene's Revlimid gets priority review Mar 3, 2006
United Press International SUMMIT, NJ, March 3 (UPI) -- Celgene said Friday the Food and Drug Administration granted Revlimid priority review for treatment of multiple myeloma. ...
Celgene's Revlimid Gets Priority Review Mar 3, 2006
International News Service, Celgene said Friday the Food and Drug Administration granted Revlimid priority review for treatment of multiple myeloma. Celgene's ...
FDA Grants Priority Review for REVLIMID(R) sNDA for Treatment of ... Mar 3, 2006
PR Newswire (press release), June 30, 2006 PDUFA Date Established Expanded Access Program to Remain Open Through FDA Action on REVLIMID sNDA SUMMIT, NJ, March 3 /PRNewswire-FirstCall ...
Millennium CEO says may form strategic partnership Mar 10, 2006
Reuters Its experimental products are in early stages of development and sales of Velcade are expected to slow as Celgene's Revlimid takes center stage. ...
Drug Stocks Tempered By Lofty Expectations Mar 4, 2006
Forbes Celgene (nasdaq: CELG - news - people ) announced last Friday that it received priority review status for a new indication for cancer drug Revlimid. ...
��：生命�纬 Mar 20, 2006
BioX, A successor to Thalomid, called Revlimid, could be approved to treat multiple myeloma as early as June in the United States if regulators give it a priority ...
Priority multiple myeloma review for Celgene drug Mar 7, 2006
Pharmaceutical Business Review The FDA has granted Celgene Corporation a priority review designation for its supplemental new drug application for Revlimid for the treatment of relapsed or ...
Celgene hits 52-week high on FDA news Mar 3, 2006
BusinessWeek ...hit a new 52-week high Friday after the drug maker said that the Food and Drug Administration will give a priority review to its drug Revlimid to treat cancer ...
Thalidomide shows promise for ALS Mar 11, 2006
Monsters and Critics.com, Kiaei said. The study appears in the Journal of Neuroscience and involved both Celgene`s Thalomid (thalidomide) and Revlimid. He ...
Thalomid® in Induction Improves Response Rates in Elderly with ... Mar 14, 2006
Cancer Consultants (press release), Lancet. Thalomid and its derivative Revlimid® (lenalidomide) are active agents for the treatment of patients with multiple myeloma. ...
Continued Treatment with Dacogen™ May Be Superior to Retreatment ... Mar 14, 2006
Cancer Consultants (press release), Vidaza® and Revlimid® are new agents that have recently been approved for the treatment of MDS; clinical trials evaluating various agents for the treatment ...
Celgene’s New Cancer Drug Gets Priority Handling Mar 3, 2006
Business New Jersey (subscription), The supplemental New Drug Application (NDA) of Revlimid, a treatment for cancers of the blood drug made by Celgene (Nasdaq: CELG) has received priority review ...
Why use free drug when you can pay $35,000? Mar 22, 2006
Globe and Mail, Gill suggested Mr. Bouchard apply under Celgene Corp.'s expanded-access program and enroll in a clinical trial with the company's newer drug, Revlimid, one he ...
Orion Hunts Winners Large And Small Mar 15, 2006
Investor's Business Daily (subscription) The firm got a boost on March 3 when it said its cancer drug Revlimid got priority review status from the Food and Drug Administration. ...
US Stock-Index Futures Fall on Rate Concern; JPMorgan Drops Mar 3, 2006
Bloomberg The drugmaker's Revlimid will receive priority review from the US Food and Drug Administration as a possible treatment for multiple myeloma, a cancer of the ...
(PRN) - Applied Innovation CTO Jack Petro to Speak at TelecomNEXT ... Mar 3, 2006
Bolsamania.com, Search ... [+. PRN) - FDA Grants Priority Review for REVLIMID(R) sNDA for Treatment of Relapsed or Refractory Multiple Myeloma ... [+. ...
Business briefs Mar 4, 2006
NorthJersey.com, SUMMIT -- Celgene Corp.'s Revlimid will receive a priority review from the US Food and Drug Administration as a treatment for multiple myeloma, the company ...
Drug, biotech stocks slip into negative territory Mar 3, 2006
Investor's Business Daily (subscription) The company said that the Food and Drug Administration will rule on whether to approve its drug Revlimid for the treatment of multiple myeloma by June 30. ...
Revlimid® Plus Dexamethasone Shows Promise in Treatment of ... 21 Dec 2005
Cancer Consultants (press release), Researchers recently reported promising results from a phase III clinical trial of Revlimid® (lenalidomide) plus dexamethasone for the treatment of multiple ...
REVLIMID(R) Clinical Results as Oral Treatment Regimen in ... Dec 13, 2005
PR Newswire (press release), 13 /PRNewswire-FirstCall/ -- Celgene Corporation (NASDAQ: CELG) announced that clinical data from a REVLIMID (lenalidomide) study in myelofibrosis (MF) were ...
Efficacy of Revlimid in patients with myelofibrosis Dec 13, 2005
Xagena.it, A Phase II study evaluated Revlimid ( Lenalidomide ) in previously treated patients with myelofibrosis, a rare blood disorder that can be fatal if untreated. ...
REVLIMID(R) IMPROVES OVERALL SURVIVAL AND DELAYS TIME TO DISEASE ... Dec 11, 2005
ITNews, Celgene Corporation (Nasdaq: CELG) announced updated clinical data from two Phase III pivotal studies evaluating REVLIMID (lenalidomide) plus dexamethasone in ...
Revlimid(R) Improves Overall Survival and Delays Time to Disease ... Dec 11, 2005
Biotech Intelligence (press release), FirstCall/ -- Celgene Corporation (NASDAQ:CELG) announced updated clinical data from two Phase III pivotal studies evaluating REVLIMID (lenalidomide) plus ...
Revlimid Improves Overall Survival and Delays Time to Disease ... Dec 12, 2005
PharmaLive.com (press release), 2005 /PRNewswire-FirstCall/ -- Celgene Corporation announced updated clinical data from two Phase III pivotal studies evaluating REVLIMID (lenalidomide) plus ...
REVLIMID(R) Clinical Results as Oral Treatment Regimen in Chronic ... Dec 12, 2005
Yahoo! News (press release) 12 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG - News) announced that clinical data from a REVLIMID study in Chronic Lymphocytic Leukemia (CLL ...
REVLIMID Clinical Results as Oral Treatment Regimen in Chronic ... Dec 12, 2005
PharmaLive.com (press release), 12 /PRNewswire-FirstCall/ -- Celgene Corporation announced that clinical data from a REVLIMID study in Chronic Lymphocytic Leukemia (CLL) were reported at an ...
REVLIMID(R) Clinical Results as Oral Treatment Regimen in ... Dec 13, 2005
Yahoo! News (press release) 13 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG - News) announced that clinical data from a REVLIMID (lenalidomide) study in myelofibrosis (MF ...
REVLIMID Clinical Results as Oral Treatment Regimen in ... Dec 13, 2005
PharmaLive.com (press release), ATLANTA, December 13, 2005 /PRNewswire-FirstCall/ -- Celgene Corporation announced that clinical data from a REVLIMID (lenalidomide) study in myelofibrosis (MF ...
Advanced multiple myeloma: Revlimid improves overall survival and ... Dec 12, 2005
Xagena.it, Updated clinical data from two Phase III pivotal studies evaluating Revlimid ( Lenalidomide ) plus Dexamethasone in previously treated multiple myeloma ...
107 Abstracts on Clinical Data Evaluating REVLIMID(R) and ... Dec 8, 2005
PR Newswire (press release), ...clinical investigators from leading cancer research centers will present data from recent and on-going clinical trials of thalidomide, and REVLIMID in multiple ...
Revlimid(R) Improves Overall Survival and Delays Time to Disease ... Dec 11, 2005
PR Newswire (press release), Updated Clinical Data Evaluating REVLIMID in Multiple Myeloma Reported at the 47th American Society of Hematology Meeting Plenary Session ATLANTA, Dec. ...
Revlimid (Lenalidomide) Clinical Results as Oral Treatment Regimen ... Dec 13, 2005
DG News ATLANTA, GA -- December 13, 2005 -- Celgene Corporation announced that clinical data from a Revlimid (lenalidomide) study in myelofibrosis (MF) were reported ...
NutriSystem the hottest stock of 2005 Dec 18, 2005
Investor's Business Daily (subscription) ...(CELG), up about 126% on the year amid excitement about its Revlimid drug, a treatment for blood and bone-marrow cancer. Revlimid ...
Millennium: Velcade set for cancer consolidation Dec 13, 2005
Pharmaceutical Business Review ...sales of Velcade and consolidate the drug's position in the multiple myeloma market, despite challenges from potential rivals such as Celgene's Revlimid. ...
Celgene Seen As 'Key Portfolio Holding' In Biotech Dec 12, 2005
Forbes ..."We are long-term positive on Celgene, based on the substantial opportunities that face Celgene in launching Revlimid," an oral drug for the treatment of ...
Celgene "neutral" Dec 12, 2005
New Ratings In a research note published this morning, the analysts mention that the company’s Phase-II study for the Revlimid single-agent in relapsed refractory ...
Combination Dexamethasone and Lenaidomide For Multiple Myeloma " ... Dec 12, 2005
DG News GA -- December 12, 2005 -- Treatment of multiple myeloma with a combination of dexamethasone and the investigational drug lenalidomide (Revlimid(R)) is ...
Myelodysplastic Syndrome - An Underserved Population Offers ... Nov 22, 2005
Genetic Engineering News, SuperGen/MGI Pharmas Dacogen and Celgenes Revlimid are in pre-registration for treatment of myelodysplastic syndrome (MDS). However ...
POST OF THE DAY Nov 23, 2005
Motley Fool Soon, Celgene will probably get approval for a drug -Revlimid- which the market will accept as direct competition for Velcade, pressuring the shares. ...
(PRN) - Newest Rhino Linings Promotion Brings Consumers the Best ... Dec 12, 2005
Bolsamania.com, ...(PRN) - REVLIMID(R) Clinical Results as Oral Treatment Regimen in Chronic Lymphocytic Leukemia Presented at the 47th American Society of Hematology Meeting ... ...
Seattle Genetics Reports Preclinical Data on its SGN-40 and SGN-70 ... Dec 13, 2005
Business Wire (press release), ...in B-cell malignancies, including Hodgkin's disease and chronic lymphocytic leukemia, and in combination with lenalidomide (Revlimid(R)). Preclinical studies ...
Millennium shares slip on downgrade Dec 7, 2005
BusinessWeek The analyst said Millennium's Velcade drug, a treatment for certain blood cancers, should see competition from Celgene Corp.'s Revlimid soon with that drug's ...
(PRN) - American Greetings Announces Revised Earnings Estimate ... ... Dec 8, 2005
Bolsamania.com, ...[+]. (PRN) - 107 Abstracts on Clinical Data Evaluating REVLIMID(R) and Thalidomide To Be Presented at The 47th American Society of Hematology Meeting ... [+. ...
Keryx Biopharmaceuticals, Inc. Announces Oral Presentation on KRX ... Dec 8, 2005
PR Newswire (press release), Dr. Anderson's group was instrumental in the development of Velcade(R), an approved drug for MM, and Revlimid(R), a drug pending potential approval for MM. ...
Top cancer advances of 2005 Dec 5, 2005
Health24.com, ...of the drug oxaliplatin in fighting colon cancer recurrence; the use of Rituxan and Bexxar combination therapy against B-cell lymphomas; Revlimid's success in ...
Top Advances in Cancer Treatment for 2005 Chosen by Oncologists Dec 2, 2005
SeniorJournal.com, The drug lenalidomide (RevLimid) reduced the need for blood transfusions in patients with MDS, a disorder of blood-forming cells that can lead to leukemia. ...
|
|
